Evidence map›Paper›PMID 16972100›Full record

Trial reportPsychopharmacology2007

fMRI predictors of treatment outcome in pediatric anxiety disorders.

Erin B McClure, Abby Adler, Christopher S Monk, Jennifer Cameron, Samantha Smith, Eric E Nelson, Ellen Leibenluft, Monique Ernst, Daniel S Pine

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.Journal of the American Academy of Child and Adolescent Psychiatry · 2021
    Trial
  4. Trial
  5. Nucleus accumbens volume as a predictor of anxiety symptom improvement following CBT and SSRI treatment in two independent samples.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  6. Trial
  7. Trial
  8. Abnormal amygdala activation profile in pedophilia.European archives of psychiatry and clinical neuroscience · 2008
    Trial
  9. Neural Markers of Treatment Response in Pediatric Anxiety and PTSD.Current topics in behavioral neurosciences · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Neurocircuitry of treatment in anxiety disorders.Biomarkers in neuropsychiatry · 2022
    Article
  14. Review
  15. Article
  16. Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years?Journal of child psychology and psychiatry, and allied disciplines · 2021
    Review
  17. Article
  18. Article
  19. Individual-Specific Analysis for Psychoradiology.Neuroimaging clinics of North America · 2020
    Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Erin B McClureDepartment of Psychology, Georgia State University, P.O. Box 5010, Atlanta, GA 30302-5010, USA. emcclure@gsu.edu
Abby Adler
Christopher S Monk
Jennifer Cameron
Samantha Smith
Eric E Nelson
Ellen Leibenluft
Monique Ernst
Daniel S Pine
National Institutes of Health · USGeorgia State University · USUniversity of Michigan · US

Funding

fMRI Studies Of Pediatric Mood And Anxiety DisordersZIAMH002781 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PINE, DANIEL · 2009 to 2025
$41.5M
Fmri Studies Of Pediatric Mood And Anxiety DisordersZ01MH002781 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PINE, DANIEL · 2002 to 2008
$1.5M
6 · The paper itself

Abstract

introductionA growing number of studies have found evidence that anxiety and depressive disorders are associated with atypical amygdala hyperactivation, which decreases with effective treatment. Interest has emerged in this phenomenon as a possible biological marker for individuals who are likely to benefit from tailored treatment approaches.

objectiveThe present study was designed to examine relationships between pretreatment amygdala activity and treatment response in a sample of anxious children and adolescents. MATERIALS AND

methodsParticipants, who were diagnosed predominantly with generalized anxiety disorder (GAD), underwent functional magnetic resonance imaging (fMRI) scanning before treatment with fluoxetine or cognitive behavioral therapy (CBT).

resultsResults indicated significant negative associations between degree of left amygdala activation and measures of posttreatment symptom improvement in the group, as a whole. DISCUSSION: Taken together with research on associations between adult amygdala activation and treatment response, these findings suggest that patients whose pretreatment amygdala activity is the strongest may be particularly likely to respond well to such widely used treatments as selective serotonin reuptake inhibitor (SSRI) medications and CBT.

Indexed as

Cognitive Behavioral TherapyMagnetic Resonance ImagingAdolescentAmygdalaAnti-Anxiety AgentsAnxiety DisordersChildEmotionsFacial ExpressionFemaleFluoxetineHumansLinear ModelsMalePatient SelectionPredictive Value of TestsAnti-Anxiety AgentsFluoxetineSelective Serotonin Reuptake Inhibitors

Identifiers

PMID16972100
OpenAlexW2039686714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.